1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PAVmed Inc.
  6. News
  7. Summary
    PAVM   US70387R1068

PAVMED INC.

(PAVM)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
1.060 USD   +4.95%
05/16PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/13PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
BU
05/12PAVMED INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference

01/06/2022 | 08:34am EDT

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference on January 11, 2022, at 11:30 AM EST. The live presentation can be accessed on the “Investor Relations” section of Lucid Diagnostics’ website at https://ir.luciddx.com/.

About Lucid Diagnostics

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Forward-Looking Statements

This press release includes forward-looking statements. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid’s clinical and preclinical studies; whether and when Lucid’s products are cleared by regulatory authorities; market acceptance of Lucid’s products once cleared and commercialized; Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, Lucid has been monitoring the COVID-19 pandemic and the pandemic’s impact on Lucid’s businesses. Lucid expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on Lucid’s businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid’s future operations, see Lucid’s Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.


© Business Wire 2022
All news about PAVMED INC.
05/16PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
05/13PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare ..
BU
05/12PAVMED INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Fin..
AQ
05/12PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Res..
BU
05/12PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12TRANSCRIPT : PAVmed Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/04Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study
PR
04/26PAVmed to Hold a Business Update Conference Call on May 12, 2022
BU
04/06PAVMED INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
04/04PAVMED : Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinic..
PU
More news
Analyst Recommendations on PAVMED INC.
More recommendations
Financials (USD)
Sales 2022 2,88 M - -
Net income 2022 -76,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,21x
Yield 2022 -
Capitalization 93,3 M 93,3 M -
Capi. / Sales 2022 32,4x
Capi. / Sales 2023 5,81x
Nbr of Employees 89
Free-Float 89,7%
Chart PAVMED INC.
Duration : Period :
PAVmed Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PAVMED INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,06 $
Average target price 6,13 $
Spread / Average Target 478%
EPS Revisions
Managers and Directors
Lishan Aklog Chairman & Chief Executive Officer
Dennis M. McGrath President, Chief Financial Officer & Secretary
Brian J. deGuzman Chief Medical Officer & Executive Vice President
Shaun M. O’Neil Chief Operating Officer & Executive Vice President
Michael J. Glennon Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
PAVMED INC.-56.91%93
THERMO FISHER SCIENTIFIC-19.05%211 433
DANAHER CORPORATION-19.00%180 198
INTUITIVE SURGICAL, INC.-36.22%80 155
SIEMENS HEALTHINEERS AG-14.49%64 824
EDWARDS LIFESCIENCES CORPORATION-21.95%61 286